Vertex Pharma (VRTX) Tops Q4 EPS by 8c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Vertex (VRTX) PT Raised to $200 at Baird; Triple Update and Strong Results
February 1, 2018 9:09 AM ESTBaird raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $186.00) while maintaining a Outperform rating.
Analyst Brian Skorney commented, "Vertex continues its momentum, releasing positive updates from its triple combination studies as well as impressive financial results and a solid... More
Vertex (VRTX) PT Raised to $183 at UBS
February 1, 2018 9:08 AM ESTUBS raised its price target on Vertex (NASDAQ: VRTX) to $183.00 (from $174.00) while maintaining a Neutral rating.
... MoreVertex (VRTX) PT Raised to $190 at Leerink Partners
February 1, 2018 7:49 AM ESTLeerink Partners raised its price target on Vertex (NASDAQ: VRTX) to $190.00 (from $175.00) while maintaining a Outperform rating.
... MoreVertex (VRTX) PT Raised to $212 at Piper Jaffray
February 1, 2018 6:42 AM ESTPiper Jaffray raised its price target on Vertex (NASDAQ: VRTX) to $212.00 (from $205.00) while maintaining a Overweight rating.
... MoreVertex Pharma (VRTX) Announces Selection of 2 Next-Generation Correctors, VX-659 & VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens
February 1, 2018 5:52 AM ESTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part of two different triple combination regimens for people with cystic fibrosis (CF). The decision to advance VX-659 and VX-445 into Phase 3 development was based on initial Phase 2 data, including... More
Vertex (VRTX) PT Raised to $203 at Citi
February 1, 2018 5:19 AM ESTCiti raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $200.00) while maintaining a Buy rating.
... MoreVertex (VRTX) PT Raised to $193 at Deutsche Bank
February 1, 2018 5:14 AM ESTDeutsche Bank raised its price target on Vertex (NASDAQ: VRTX) to $193.00 (from $175.00) while maintaining a Buy rating.
... MoreVertex (VRTX) PT Raised to $200 at Barclays
February 1, 2018 3:48 AM ESTBarclays raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $180.00) while maintaining a Overweight rating.
... More